RxDoctor Payments Data

Adam Schussheim, MD

Nuclear Cardiology · Fairfield, CTNPI 1104821925

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,304 of the $9,630 with a category attached, or 86.2%. 4 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 55.5% of the total. Reporting peaked in 2019 at $9,242 and has fallen 96.8% since, to $300 in 2025.

$9,630in general payments, 2019–2025

Across 22 payments — averaging $437.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$5K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Chiesi USA, Inc.$300
  • E.r. Squibb & Sons, L.L.C.$69
$1,174,956in research payments, 2019–2025

Across 35 payments — averaging $33,570 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$746K
  • Eli Lilly$429K

What the payments were for

  • Speaking & faculty fees$8,30486%
  • Travel & lodging$7478%
  • Food & beverage$5616%
  • Education$190%

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$280,809
Medicare patients
1,156
Services billed
4,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$1,217,902
EliquisApixaban626$817,263
FarxigaDapagliflozin Propanediol197$262,814
XareltoRivaroxaban214$254,422
CamzyosMavacamten25$201,014
EntrestoSacubitril/Valsartan202$200,380
JardianceEmpagliflozin84$121,748
OzempicSemaglutide88$92,936
Praluent PenAlirocumab51$63,735
VascepaIcosapent Ethyl80$61,899
Repatha SureclickEvolocumab70$59,067
BrilintaTicagrelor24$24,058
NexlizetBempedoic Acid/Ezetimibe18$18,844
Rosuvastatin Calcium1,328$17,764
NexletolBempedoic Acid20$13,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$69$201,01425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →